I suspect comorbidities might be captured as part of the study, but doubt they are factored into primary and secondary endpoints. They should keep the endpoints on task and clean to ensure the arrow hits the mark. For this phase trial I think they will lean into well understood biomarkers which stand in for some of the pathology they ultimately intend to treat.

That said a secondary analysis of comorbidity might be a fruitful “tell” to inform future studies or capture the interest of potential partners. I would find it surprising if the protocol is not capturing that patient-level data.

I am keenly interested to see what ultimately hits clinicaltrials.gov

https://m.investorshangout.com/post/view?id=6654800